Showing 1 - 6 results of 6 for search 'Lukas Flatz', query time: 0.02s Refine Results
  1. 1
    Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis

    Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review... by Konstantinos Lallas, Eftychia Chatziioannou, Derya Durak, Georg Frey, Lina Maria Serna-Higuita, Marie-Lena Rasch, Athanassios Kyrgidis, Eleni Timotheadou, Zoe Apalla, Ulrike Leiter, Lukas Flatz, Lukas Flatz, Aimilios Lallas, Teresa Amaral, Teresa Amaral

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Comparative real-world outcomes of stage III melanoma patients treated with talimogene laherparepvec or interleukin 2

    Comparative real-world outcomes of stage III melanoma patients treated with talimogene laherparepvec or interleukin 2 by Markus Reitmajer, Lena Nanz, Nina Müller, Ulrike Leiter, Teresa Amaral, Valentin Aebischer, Lukas Flatz, Andrea Forschner

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Swiss Recommendations for Systemic Therapies in Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma

    Swiss Recommendations for Systemic Therapies in Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma by Mirijam Nägeli, Joanna Mangana, Roger von Moos, Lukas Flatz, Robert E. Hunger, Rastine Merat, Olivier Gaide, Marco Siano, Reinhard Dummer

    Published 2021-06-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and BRAF V600 mutation

    Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and BRAF V600 mutation by Julia Forschner, Julia Huynh, Christopher Schroeder, Sorin Armeanu-Ebinger, Olga Seibel-Kelemen, Axel Gschwind, Irina Bonzheim, Thomas K. Eigentler, Teresa Amaral, Stephan Ossowski, Lukas Flatz, Claus Garbe, Andrea Forschner, Markus Reitmajer

    Published 2025-08-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer

    C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer by Stefan Diem, Markus Joerger, Fiamma Berner, Lukas Flatz, Niklas Klümper, Manuel Ritter, Michael Hölzel, Jörg Ellinger, Peter Brossart, Annkristin Heine, Jonas Saal, Christa Lichtensteiger, Nina Wyss, Franz Georg Bauernfeind, Sabine Schmid, Martin Frueh, Tobias Bald

    Published 2022-03-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection.

    Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection. by Rami Sommerstein, Lukas Flatz, Melissa M Remy, Pauline Malinge, Giovanni Magistrelli, Nicolas Fischer, Mehmet Sahin, Andreas Bergthaler, Sebastien Igonet, Jan Ter Meulen, Dorothée Rigo, Paolo Meda, Nadia Rabah, Bruno Coutard, Thomas A Bowden, Paul-Henri Lambert, Claire-Anne Siegrist, Daniel D Pinschewer

    Published 2015-11-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: